Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension
Authors:
- Fabio AngeliFabio Angeli
- Paolo VerdecchiaPVPaolo Verdecchia
- Chiara PascucciCPChiara Pascucci
- Cristina PoltronieriCPCristina Poltronieri
- Gianpaolo ReboldiGRGianpaolo Reboldi
- 21 December 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 9 (3) , 379-385
Abstract
Azilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%. This new agent induces a potent and long-lasting antihypertensive effect. The effective therapeutic antihypertensive dosages of azilsartan medoxomil in humans vary from 40 to 80 mg/day. The authors review the results of clinical trials published in journals indexed in Medline, Scopus and Google Scholar. Primarily the authors discuss articles that analyze the safety and efficacy of azilsartan in lowering blood pressure. Clinical trials have demonstrated that azilsartan is superior to other angiotensin-receptor blockers in lowering blood pressure. However, the clinical blood pressure trials of azilsartan published to date have been mainly conducted in patients without serious comorbidities and it is not clear if azilsartan has advantages over other angiotensin-receptor blockers in the treatment of these types of hypertensive patients. In addition, it remains to be determined whether the specific pharmacologic and pharmacokinetic characteristics of azilsartan will have a clinically significant impact on long-term cardiovascular outcomes.Keywords
This publication has 43 references indexed in Scilit:
- Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic HypertensionHypertension, 2012
- Critical evaluation of the efficacy and tolerability of azilsartanVascular Health and Risk Management, 2012
- Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical studyHypertension Research, 2012
- Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of HypertensionAnnals of Pharmacotherapy, 2011
- Azilsartan Medoxomil: A New Angiotensin Receptor BlockerClinical Therapeutics, 2011
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure MonitoringThe Journal of Clinical Hypertension, 2011
- Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 HypertensionHypertension, 2011
- In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function StudiesThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood PressureThe Journal of Clinical Hypertension, 2011
- Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole BioisosteresJournal of Medicinal Chemistry, 1996